LONDON and NEW YORK, April  08, 2024  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled "KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease" originally planned for April 9th, 2024 at 12:00 PM ET until May 2024. The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.

OKYO is planning to make a presentation at "Dry Horizons Symposium Navigating the Future of Dry Eye Research", an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

Date: Friday May 3, 2024, 2:50-3:45 PM PST
Venue: Four Seasons Seattle, WA
Presenter: Gary Jacob, PhD, Chief Executive Officer

About Dry Horizons Symposium
Uniting clinical leaders and industry innovators to tackle significant challenges in the dry eye market. With the rising prevalence of dry eye disease, the shortcomings of existing treatments, as well as new opportunities for advancing clinical pathways based on recent successful therapies, this symposium will provide in-depth coverage of the global landscape of Dry Eye and the opportunity for further innovation. From the impact of technology use on eye health, to unexplored therapeutics, to accelerating research and development, this new event will showcase the urgent need for innovative clinical solutions to benefit current and future patients.

About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.